Wellcome Trust Sanger Institute
www.sanger.ac.ukThe Sanger Institute is a genome research institute primarily funded by the Wellcome Trust. Its purpose is to further the knowledge of genomes, particularly through large scale sequencing and analysis.
The Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992 as the focus for UK sequencing efforts. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms such as mouse and zebrafish, and more than 90 pathogen genomes. In October 2001, new funding was awarded by the Wellcome Trust to support a new range of post-genomic programmes designed to understand the biological function of genes and their relevance to our health. These programmes are built around a Faculty of more than 30 senior researchers.
The Wellcome Trust is an independent research-funding charity, established under the will of Sir Henry Wellcome in 1936. It is funded from a private endowment which is managed with long-term stability and growth in mind. The Trust's mission is to foster and promote research with the aim of improving human and animal health.
The Wellcome Trust has recently approved a £334 million funding envelope for the Institute's new strategic plan 2006 - 2011. Over the next five years the focus will be on activity in human, mouse and zebrafish genetics, vertebrate functional proteomics, pathogen genetics and genomics, genome biology and informatics. Future faculty recruitment is being targeted in the area of statistics, malaria genetics and/or biology.
Staff
 Allan Bradley, DirectorProfessor Bradley completed his PhD studies in genetics at the University of Cambridge in 1984. During his time in Cambridge Dr Bradley co-developed the embryonic stem cell system with Elizabeth Robertson and Martin Evans. Embryonic stem cells can be isolated from mouse embryos, grown and modified in culture, and then used to produce mice carrying defined mutations. In 1987, Dr Bradley moved to Baylor College of Medicine, Houston, Texas as an Assistant Professor and was promoted to full Professor in 1995. In 1993 Dr Bradley received an appointment as a Howard Hughes Medical Institute Investigator. While at Baylor, Dr Bradley's laboratory pursued the analysis of gene function using knockout mice and has published the function of numerous genes using this technology. Dr Bradley's laboratory has also developed novel methods to engineer the genomes of mice, including point mutations and large chromosomal changes. Dr Bradley is the author of over 160 scientific articles and book chapters. He has been active in commercialising technology from his laboratory by founding several companies including a publicly traded genomics company, Lexicon Genetics Inc. In November 2000, Dr Bradley assumed his appointment as Director of the Institute. |
Contact details
Hinxton
Cambridge
CB10 1SA, UK
Tel: +44 (0)1223 834244
Fax: +44 (0)1223 494919
